HUMAGLOBIN

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Primary immunodeficiency disorders
• Secondary immunodeficiency (e.g. due to HIV infection)
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Immune thrombocytopenic purpura (ITP)
• Kawasaki disease
• Prevention of infections in at-risk populations (e.g. following bone marrow transplant)

Dosage

Children: Refer to the BNF for Children for age-appropriate dosing guidelines; specific doses depend on the clinical condition and patient age.

Adults: Refer to specific guidelines for dosing based on indication; typically varies based on clinical scenario and patient condition.

Mechanism of action

Immunoglobulin exerts its effects primarily through the neutralization of pathogens and toxins, opsonization, and the activation of the complement system. It modulates immune responses by influencing the activity of various immune cells, including B cells, T cells, and macrophages, thereby enhancing antibody production and regulating inflammation.

Pharmacodynamics

The pharmacodynamics of immunoglobulin involve its ability to bind to specific antigens, effectively neutralizing them and facilitating their clearance. It also plays a crucial role in modulating the immune response, providing immediate passive immunity and promoting the establishment of active immunity over time. The diverse mechanisms through which immunoglobulin operates include antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of pro-inflammatory cytokines.

Pharmacokinetics

Immunoglobulin is typically administered intravenously or subcutaneously. After administration, it is distributed throughout the extracellular space. The half-life of immunoglobulin varies but is generally in the range of 21 to 30 days, depending on the specific formulation and the patient's individual characteristics. It is primarily eliminated through the reticuloendothelial system, with catabolism occurring in various tissues.

Contra-indications

• Hypersensitivity to immunoglobulin preparations
• Selective IgA deficiency with a history of hypersensitivity
• Severe hyperprolinemia

Adverse effects

• Headache
• Nausea
• Fever
• Chills
• Fatigue
• Rash
• Anaphylactic reactions
• Thromboembolic events

Interactions

• Live attenuated vaccines may be less effective if administered concurrently with immunoglobulin therapy
• Caution is advised when administering with other blood products

Precautions

• Monitor for signs of anaphylaxis during and after administration
• Use with caution in patients with renal impairment
• Hydrate adequately to prevent renal dysfunction
• Consider the risk of thrombosis in patients with a history of thromboembolic events

Pregnancy

Immunoglobulin can be used during pregnancy if indicated, as it is considered safe based on available data.

Breast-feeding

Immunoglobulin is excreted in breast milk, but is generally considered safe during breastfeeding.

Storage

Store at 2-8 degrees Celsius. Do not freeze. Protect from light. Use before expiry date.

Formulations

• Intravenous immunoglobulin (IVIG)
• Subcutaneous immunoglobulin (SCIG)
• Intramuscular immunoglobulin (IMIG)

Indications

• Primary immunodeficiency syndromes
• Secondary immunodeficiency due to various conditions
• Autoimmune diseases such as immune thrombocytopenic purpura (ITP)
• Kawasaki disease
• Guillain-Barré syndrome
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Certain infections in immunocompromised patients

Dosage

Children: Refer to the BNF for Children for specific dosing information tailored for pediatric patients.

Adults: Refer to the BNF for specific dosing information based on the condition being treated. Doses can vary widely based on individual patient factors and clinical situations.

Mechanism of action

IVIG acts by providing a broad spectrum of antibodies that can neutralize pathogens and modulate the immune response. It is thought to work through several mechanisms including suppressing pro-inflammatory cytokines, enhancing phagocytosis, and promoting the regulation of T cells. It can also inhibit the activation of complement pathways and neutralize autoantibodies in autoimmune diseases.

Pharmacodynamics

The pharmacodynamics of IVIG are characterized by its effects on the immune system, including the enhancement of antibody-mediated responses, modulation of immune cell function, and reduction of inflammatory responses. The therapeutic effects can vary based on the dosage and the specific condition being treated, with some patients experiencing rapid relief from symptoms while others may require prolonged treatment to achieve optimal responses.

Pharmacokinetics

IVIG is typically administered intravenously, leading to rapid absorption into the bloodstream. Its half-life ranges from 21 to 30 days, depending on the individual patient's metabolic rate and other factors. The bioavailability of IVIG is nearly 100% when given intravenously. It is distributed throughout the body's extracellular fluid and is metabolized primarily by the reticuloendothelial system, with antibodies being cleared through cellular uptake and degradation.

Contra-indications

• Hypersensitivity to immunoglobulin preparations
• IgA deficiency with antibodies against IgA
• Severe systemic reactions to previous IVIG therapy

Adverse effects

• Headache
• Fever
• Chills
• Nausea
• Vomiting
• Fatigue
• Myalgia
• Rash
• Thromboembolic events

Interactions

• Live attenuated vaccines may be less effective if administered shortly before or after IVIG
• Corticosteroids may alter the immune response

Precautions

• Monitor for signs of thrombosis, especially in patients with risk factors
• Use with caution in patients with renal impairment
• Patients with a history of anaphylactic reactions should be monitored closely

Pregnancy

IVIG is generally considered safe during pregnancy; however, consult with a healthcare professional for individual cases.

Breast-feeding

IVIG is excreted in breast milk; its effects on nursing infants are not fully established, consult with a healthcare professional.

Storage

Store in a refrigerator between 2°C and 8°C. Do not freeze. Protect from light.

Formulations

• Intravenous immunoglobulin (IVIG) solution
• Subcutaneous immunoglobulin (SCIG) solution

Indications

• Primary immunodeficiency syndromes
• Secondary immunodeficiency
• Immunomodulation in certain autoimmune disorders
• Prevention of infections in patients undergoing immunosuppressive therapy

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations in pediatric patients, as it varies based on age, weight, and clinical condition.

Adults: Refer to the BNF for specific dosing recommendations for adults, as it varies based on clinical indications and patient circumstances.

Mechanism of action

Normal immunoglobulin works by providing a broad spectrum of antibodies that neutralize pathogens and enhance the immune response. These antibodies bind to pathogens, facilitating their removal by immune cells and providing immediate passive immunity against infections.

Pharmacodynamics

The pharmacodynamic effects of normal immunoglobulin include the neutralization of toxins and pathogens, opsonization, and enhancement of phagocytosis. It modulates immune responses and provides immediate humoral immunity, particularly in individuals with inadequate antibody production.

Pharmacokinetics

Normal immunoglobulin is administered intravenously or subcutaneously. After administration, it is distributed throughout the body, with a half-life of approximately 21 to 30 days. It is metabolized by the reticuloendothelial system, and the rate of clearance can vary based on individual patient factors and the presence of underlying conditions.

Interactions

• normal immunoglobulin + monoclonal antibodies: Severe (affects effects)
• normal immunoglobulin + dinutuximab: Severe (affects effects)
• normal immunoglobulin + live vaccines, measles, mumps and rubella vaccine, live, rotavirus vaccine, typhoid vaccine, oral, varicella-zoster vaccine: Unknown (decreases efficacy)
• normal immunoglobulin + bacillus Calmette-Guérin vaccine: Unknown (decreases efficacy)
• normal immunoglobulin + herpes-zoster vaccine: Unknown (decreases efficacy)
• normal immunoglobulin + live: Unknown (decreases efficacy)
• normal immunoglobulin + influenza vaccine, live: Unknown (decreases efficacy)

Pregnancy

Consult relevant guidelines for use in pregnancy.

Breast-feeding

Consult relevant guidelines for use during breastfeeding.

Storage

Store at 2-8°C. Do not freeze.